Replies to post #683 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Roche’s R1626 HCV polymerase inhibitor has shown unacceptable neutropenia in the existing phase-2 trial (#msg-13986782). As a result, R1626 will have to be tested in a second phase-2 trial using a lower dose.

Source: Roche’s 1Q07 CC